跳至主要内容
临床试验/NCT06154434
NCT06154434已完成1 期

An Open Label, Randomized, Fasting, Single-dose, Two-period Crossover Study to Compare the Bioequivalence of Chlorpromazine HCl 100mg Tablets After Oral Administration in Healthy Subjects.

Whanin Pharmaceutical Company1 个研究点 分布在 1 个国家目标入组 70 人开始时间: 2018年12月6日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
发起方
入组人数
70
试验地点
1
主要终点
AUClast

研究概览

简要总结

This clinical study is an open label, randomized, fasting condition, single-dose, two-period crossover study to compare the bioequivalence of Chlorpromazine HCl 100mg Tablets after oral administration in healthy subjects.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Other
盲法
None

入排标准

年龄范围
19 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Healthy subjects, over the age of 19 years old
  • Weight: At least 50.0 kg and Body mass index (BMI) between 18.0-30.0 kg/m
  • All subjects should be judged normal and healthy during a pre-study medical evaluation
  • Subjects who has no birth or chronic disease and must be in good health as determined by physical exmination and medical tests including biochemistry, urinalysis, serology and hematology etc in serum/urine.
  • Subject is willing to participate and to Sign written informed consent form
  • Female subjects of childbearing age who use contraception other than hormonal contraception.
  • Subjects who has no history of psychical disorder within the last five years

排除标准

  • Subjects who have a medical history specified in protocol
  • Subjects who are expected to have the prohibited medication and activity etc. during the study period
  • Subjects who can not comply with requirements as per protocol
  • Pregnant women or breast-feeding women or men and women who has possibility of pregnancy
  • Subjects who are not suitable for the clinical trial

研究组 & 干预措施

Group A

Experimental

干预措施: Chlorpromazine HCl 100mg Tablets (Drug)

Group B

Experimental

干预措施: Chlorpromazine HCl 100mg Tablets (Drug)

结局指标

主要结局

AUClast

时间窗: Up to 72 hours

Cmax

时间窗: Up to 72 hours

次要结局

未报告次要终点

研究者

发起方
Whanin Pharmaceutical Company
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验